Exclusion Criteria
PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation
boolean
UVB therapy anywhere on the patient within 14 days prior to randomisation
boolean
Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton
boolean
Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation
boolean
Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton
boolean
Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation
boolean
Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study
boolean
Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis
boolean
Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin
boolean
Known or suspected severe renal insufficiency or severe hepatic disorders
boolean
Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia
boolean
Trial subjects should be using an adequate method of contraception
boolean